Blueprint Medicines (BPMC) PT Raised to $52 at Jefferies
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $44.97 +5.64%
Rating Summary:
16 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 33
Rating Summary:
16 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 13 | New: 33
Join SI Premium – FREE
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Jefferies raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $52.00 (from $42.00) while maintaining a Buy rating.
"With add'l clinical data for 2 lead candidates (BLU-285, BLU-554) in 2017 likely to strengthen their therapeutic potential, and added clarity around approval path for BLU-285 in GIST as soon as 1H17, we see opportunity for further upside despite recent run-up in share price," analyst Carmen Augustine said.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarana Menara Nusantara Tbk (TOWR:JK) (SMNUF) PT Lowered to R$1,000 at Citi
- UBS cuts softlines retailers including Foot Locker as view becomes increasingly bearish
- China Resources Mixc Lifestyle (1209:HK) PT Raised to HK$56 at CLSA
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
